Salesforce vs. Veeva: A High-Stakes Battle for Pharma CRM Dominance
The pharmaceutical software industry is witnessing a seismic shift as Salesforce Inc. (CRM) positions itself to challenge Veeva Systems Inc. (VEEV), the long-time leader in pharmaceutical customer relationship management (CRM). Salesforce has already signed over 40 customers for its upcoming life sciences platform, including a major player among the top three global pharmaceutical companies, according to a Bloomberg report citing Jeff Amann, Salesforce’s executive vice president for industry-specific software. Notably, some of these new clients are transitioning away from Veeva, signaling a potential reshaping of the market.
Veeva’s Longstanding Reign
Veeva, which commands an estimated 80% share of the pharmaceutical CRM market, has built its dominance through highly specialized software tailored for the life sciences sector. The company, projected to generate .72 billion in revenue this fiscal year, provides not only CRM tools but also solutions for drug development tracking and analytics. Historically, Veeva’s CRM offerings were built on Salesforce’s platform under a non-compete agreement that allowed both companies to thrive without overlapping in the life sciences space.
This partnership dissolved in late 2022 when Veeva decided to break away from Salesforce’s infrastructure, opting to develop its own suite of applications. This decision effectively ended the collaboration and opened the door for Salesforce to directly target Veeva’s core market with its own life sciences CRM solution.
Salesforce’s Strategic Push
Salesforce’s move into the pharmaceutical sector comes at a time of increasing demand from life sciences companies seeking alternatives to Veeva’s platform. According to Amann, many of these companies expressed a desire to avoid the disruption of switching away from Salesforce’s ecosystem, prompting the company to develop a dedicated life sciences product.
The market has responded to this shift. On Tuesday, Veeva’s shares dropped over 3%, closing at $217.43, while Salesforce’s stock ticked up to $344.43, reflecting investor confidence in Salesforce’s strategy. Salesforce is now doubling down on its efforts, expanding its development teams and refining its life sciences product, which is set for a September launch. The company is reportedly engaged in discussions with several leading pharmaceutical firms as it seeks to erode Veeva’s market share.
Veeva’s Counterattack
Despite the emerging competition, Veeva remains confident. Paul Shawah, Veeva’s executive vice president, pointed out that most of its large clients, including industry giants like GSK Plc and Novo Nordisk A/S, have reaffirmed their loyalty. While Veeva has lost one of its top 20 customers to Salesforce, Shawah emphasized that Veeva’s deep focus on the complexities of the pharmaceutical industry gives it a significant edge in product optimization and pricing.
Veeva is also using its newfound freedom from Salesforce to expand its product offerings. Previously restricted by its agreement with Salesforce, the company is now developing a CRM that will operate entirely on its own platform. This move allows Veeva to explore areas like customer service and patient management—domains that were previously off-limits.
Shawah has cautioned potential defectors about Salesforce’s readiness to compete in life sciences, asserting that Veeva’s years of experience in the sector make its offerings more reliable and cost-effective.
A Battle That Will Shape the Industry
The competition between Salesforce and Veeva represents a classic clash between a market leader and an innovative challenger. Salesforce, a global CRM powerhouse, is leveraging its scale, AI capabilities, and integration strengths to gain a foothold in the pharmaceutical market. Meanwhile, Veeva is doubling down on its specialized expertise and long-standing relationships with life sciences companies.
As the rivalry intensifies, its impact will extend beyond market share. The technological evolution of pharmaceutical CRM solutions—including advancements in AI, data management, and compliance—will likely accelerate, reshaping how pharmaceutical companies manage customer relationships and navigate complex regulatory environments.
The outcome of this battle will set the tone for the future of CRM in life sciences, influencing both the competitive landscape and the technological trajectory of the industry.
Expanding its reach beyond CRM, Salesforce.com has launched a new service called AppExchange OEM Edition, aimed at non-CRM service providers. Read more
In Marc Benioff's own words How did salesforce.com grow from a start up in a rented apartment into the world's Read more
Salesforce.com, a prominent figure in cloud computing, has finalized a deal to acquire Jigsaw, a wiki-style business contact database, for Read more
Following swiftly after last week's successful launch of Financial Services Cloud, Salesforce has announced the second installment in its series Read more
